LARVOL Found The First Cancer-Focused Social Listening Platform For Pharma And Oncology
LARVOL, a major supplier of information and intelligence solutions for its pharmaceutical and biotech business, today announced the launching of VIEW, the very first curated societal listening and opinion analysis platform centered on Twitter-verified oncologists, researchers, along Digital Opinion Leaders. Access to the curated advice will enable pharma entrepreneurs, competitive intelligence, and health care affairs teams to create educated, up-to-the-minute decisions affecting their oncology drug placement.
VIEW signifies a new era in the relationship between pharmaceutical teams along with the doctors they rely on insights into the clinical effectiveness of their goods. The internet platform introduces trending cancer information curated by specialists, together with sentiment evaluation, influencer standing, and pulling information from Twitter’s top oncologists. This concentrated analysis empowers drug developers and entrepreneurs for an accurate read on the competitive landscape and also to efficiently identify and participate with DOLs in oncology.
“Top oncologists are currently utilizing Twitter to discuss their views on trials, therapies, and also the expertise of the patients in real-time,” states LARVOL Founder and CEO Bruno Larvol. “Enforcement teams understand the value of the DOLs as specialists in their area and influencers of the peers, but the cancer dialog is proceeding too fast for everyone to translate by themselves.
LARVOL’s specialist analysts concentrate on the real-time action of over 1,500 confirmed oncologists on Twitter. Analysts manually code and review every talk to express that the physician’s opinion of trending information is negative or positive. The outcome is a purposeful and authentic film for its pharma teams of the community’s reaction to breaking cancer information.
